Psychedelic medicine is an emerging field that uses substances like MDMA to produce non-ordinary states of consciousness. MDMA is in phase-3 FDA trials for treating PTSD and was designated a breakthrough therapy in 2017 due to its safety and efficacy when combined with manualized therapy. Historical and contemporary racial mistreatment triggers physiological stress responses in Black people, similar to those in anxiety disorders. The paper explores how entheogens in psychedelic-assisted therapy could address negative race-based experiences and promote healing among BIPOC. It also discusses the ethical need for culturally competent providers and for recruiting BIPOC into research and training.
From 2015 to 2019, the proportion of Americans who perceived 'great' risk in trying LSD fell from 70.5% to 64.8%, a statistically significant linear decline. Lower perceived risk was associated with later survey year, personal LSD use, younger age, higher education, male gender, identifying as a sexual minority, and past-year psychological distress. Higher perceived risk was linked to identifying as Black or Hispanic, past-year suicide attempt, and having children at home. Among respondents under 18, Hispanic identity showed no association, and male gender was linked to higher perceived risk. Most Americans still perceive great risk in trying LSD.
Practice manuals and clinical guidelines for psychedelic-assisted therapy (PAT) show varying alignment with the American Psychological Association's 2017 Multicultural Guidelines, but none offer teachable instructions for delivering culturally responsive care. This gap points to a need for more comprehensive training of PAT facilitators to ensure equitable treatment for diverse populations.